POST Online Media Lite Edition


OpGen appoints R. Don Elsey to board

Staff Writer |
Gaithersburg, Md., USA - OpGen, a precision medicine company, announced the appointment R. Don Elsey to the company’s board of directors and audit committee, effective February 21, 2019.

Mr. Elsey will serve as chairman of the board’s audit committee and will stand for reelection for a one-year term at the company’s next annual meeting of stockholders, to be held in June 2019.

Mr. Elsey is a biotechnology, life sciences and high technology industries veteran with more than three decades of experience in international financial management and operations with both large and small companies.

Most recently Mr. Elsey served as chief financial officer of Senseonics, Inc., a position he held from February 2015 to January 2019.

Prior to Senseonics, he was chief financial officer of Regado Biosciences Corporation.

Mr. Elsey has also served as chief financial officer of LifeCell Corporation, a privately held regenerative medicine company, and as chief financial officer of Emergent Biosolutions, a biodefense company.

He also has held senior financial positions at BioVeris Corporation, Igen, Inc. and PE Corporation (Applera).